Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 1;109(2):81-82.
doi: 10.1097/JS9.0000000000000044.

A new kind of diabetes medication approved by the FDA: is there hope for obesity?

Danisha Dhirani  1 , Ahmad Shahid  1 , Hassan Mumtaz  2
Affiliations

A new kind of diabetes medication approved by the FDA: is there hope for obesity?

Danisha Dhirani et al. Int J Surg. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no financial conflict of interest with regard to the content of this report.

Sponsorships or competing interests that may be relevant to the content are disclosed at the end of this article.

References

    1. Jeon WS, Park CY. Antiobesity pharmacotherapy for patients with type 2 diabetes: focus on long-term management. Endocrinol Metab 2014;29:410. - PMC - PubMed
    1. FDA approves drug tirzepatide for type 2 diabetes. (n.d.). Accessed June 2, 2022. https://www.healthline.com/health-news/fda-approves-new-drug-tirzepatide... .
    1. FDA. FDA approves novel, dual-targeted treatment for type 2 diabetes. (n.d.). Accessed June 2, 2022. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-d... .
    1. Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol 2021;20:225. - PMC - PubMed
    1. Willard FS, Douros JD, Gabe MBN, et al. . Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 2020;5:17. - PMC - PubMed